New drug cocktail aims to keep myeloma at bay after transplant
NCT ID NCT02659293
First seen Mar 08, 2026 · Last updated May 20, 2026 · Updated 8 times
Summary
This study tests whether adding two drugs (carfilzomib and dexamethasone) to the standard maintenance drug lenalidomide after a stem-cell transplant can keep multiple myeloma from coming back longer. About 180 adults who have already had a transplant and are in at least stable disease will be randomly assigned to one of two groups. The goal is to see if the three-drug combination improves progression-free survival and reduces signs of cancer at a microscopic level.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Polish Myeloma Consortium
Poznan, Poland
-
University of Chicago
Chicago, Illinois, 60637, United States
-
Wayne State University - Karmanos Cacner Institute
Detroit, Michigan, 48201, United States
Conditions
Explore the condition pages connected to this study.